JP2013528563A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528563A5
JP2013528563A5 JP2012544363A JP2012544363A JP2013528563A5 JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5 JP 2012544363 A JP2012544363 A JP 2012544363A JP 2012544363 A JP2012544363 A JP 2012544363A JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
composition according
retinal
retinopathy
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544363A
Other languages
English (en)
Japanese (ja)
Other versions
JP5878128B2 (ja
JP2013528563A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2011/059479 external-priority patent/WO2011129461A1/en
Publication of JP2013528563A publication Critical patent/JP2013528563A/ja
Publication of JP2013528563A5 publication Critical patent/JP2013528563A5/ja
Application granted granted Critical
Publication of JP5878128B2 publication Critical patent/JP5878128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2012544363A 2010-04-12 2011-04-12 網膜疾患を処置するための方法および眼科用組成物 Active JP5878128B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US32333810P 2010-04-12 2010-04-12
US32334210P 2010-04-12 2010-04-12
US61/323,342 2010-04-12
US61/323,338 2010-04-12
US32681110P 2010-04-22 2010-04-22
US61/326,811 2010-04-22
US36294510P 2010-07-09 2010-07-09
US61/362,945 2010-07-09
US40823710P 2010-10-29 2010-10-29
US61/408,237 2010-10-29
PCT/JP2011/059479 WO2011129461A1 (en) 2010-04-12 2011-04-12 Method and ophthalmic composition for treating retinal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015194346A Division JP2016026182A (ja) 2010-04-12 2015-09-30 網膜疾患を処置するための方法および眼科用組成物

Publications (3)

Publication Number Publication Date
JP2013528563A JP2013528563A (ja) 2013-07-11
JP2013528563A5 true JP2013528563A5 (enExample) 2014-05-29
JP5878128B2 JP5878128B2 (ja) 2016-03-08

Family

ID=44798822

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012547193A Expired - Fee Related JP5686819B2 (ja) 2010-04-12 2011-04-12 黄斑浮腫を処置するための医薬組成物
JP2012544363A Active JP5878128B2 (ja) 2010-04-12 2011-04-12 網膜疾患を処置するための方法および眼科用組成物
JP2015194346A Pending JP2016026182A (ja) 2010-04-12 2015-09-30 網膜疾患を処置するための方法および眼科用組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012547193A Expired - Fee Related JP5686819B2 (ja) 2010-04-12 2011-04-12 黄斑浮腫を処置するための医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015194346A Pending JP2016026182A (ja) 2010-04-12 2015-09-30 網膜疾患を処置するための方法および眼科用組成物

Country Status (9)

Country Link
US (2) US20110275711A1 (enExample)
EP (2) EP2558104A4 (enExample)
JP (3) JP5686819B2 (enExample)
KR (2) KR20130099812A (enExample)
CN (2) CN102933217A (enExample)
AR (1) AR080888A1 (enExample)
CA (2) CA2795723A1 (enExample)
TW (2) TW201204366A (enExample)
WO (2) WO2011129461A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600040A (en) 2009-11-27 2014-03-28 R Tech Ueno Ltd Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method.
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
CA2865132A1 (en) * 2012-02-22 2013-08-29 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
JP6898429B2 (ja) * 2016-08-24 2021-07-07 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン 黄斑変性症を治療するためのエンタカポン関連化合物
CN113966236A (zh) * 2019-04-03 2022-01-21 再生生物股份有限公司 眼睛病状的基因疗法
EP4094759A1 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
AU2021217358A1 (en) 2020-02-06 2022-09-08 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
EP4329753A4 (en) 2021-04-30 2025-02-26 Perfuse Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE409491T1 (de) * 2000-01-18 2008-10-15 Merck & Co Inc Orhthalmologische zusammenstellungen zur behandlung von ocularer hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
KR101118935B1 (ko) * 2003-08-21 2012-03-13 가부시키가이샤 아루떼꾸 우에노 안과용 조성물
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2013528563A5 (enExample)
Mayama Calcium channels and their blockers in intraocular pressure and glaucoma
MX385629B (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
JP2010285434A5 (enExample)
MX361520B (es) Composiciones y métodos para tratar edema ocular, neovascularización y enfermedades relacionadas.
RU2015117536A (ru) Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний
JP2015526467A5 (enExample)
WO2015135306A1 (zh) 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物
WO2011151685A8 (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
RU2012134639A (ru) Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза
Xin et al. Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration
WO2008020032A8 (en) Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
FI2765988T3 (fi) Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus
WO2007075720A3 (en) Topical mecamylamine formulations for ocular administration and uses thereof
JP2015523986A5 (enExample)
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
NZ594728A (en) Use of deferiprone for treatment and prevention of iron-related eye disorders
HRP20192256T1 (hr) Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
JP7461667B2 (ja) ナノ低分子ペプチドｆｈ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用
JP2012505928A5 (enExample)
Querques et al. Intravitreal pegaptanib sodium for Irvine-Gass syndrome
JP2015027980A5 (enExample)